Jeffrey Ivan Gordon
University of Washington
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jeffrey Ivan Gordon.
Nature Immunology | 2004
Justin L. Sonnenburg; Largus T. Angenent; Jeffrey Ivan Gordon
The gut contains our largest collection of resident microorganisms. One obvious question is how microbial communities establish and maintain themselves within a perfused intestine. The answers, which may come in part from observations made by environmental engineers and glycobiologists, have important implications for immunologists who wish to understand how indigenous microbial communities are accommodated. Here we propose that the mucus gel layer overlying the intestinal epithelium is a key contributor to the structural and functional stability of this microbiota and its tolerance by the host.
Proceedings of the National Academy of Sciences of the United States of America | 2009
Amanda L. Lewis; Nolan Desa; Elizabeth E. Hansen; Yuriy A. Knirel; Jeffrey Ivan Gordon; Pascal Gagneux; Victor Nizet; Ajit Varki
Sialic acids (Sias) are nonulosonic acid (NulO) sugars prominently displayed on vertebrate cells and occasionally mimicked by bacterial pathogens using homologous biosynthetic pathways. It has been suggested that Sias were an animal innovation and later emerged in pathogens by convergent evolution or horizontal gene transfer. To better illuminate the evolutionary processes underlying the phenomenon of Sia molecular mimicry, we performed phylogenomic analyses of biosynthetic pathways for Sias and related higher sugars derived from 5,7-diamino-3,5,7,9-tetradeoxynon-2-ulosonic acids. Examination of ≈1,000 sequenced microbial genomes indicated that such biosynthetic pathways are far more widely distributed than previously realized. Phylogenetic analysis, validated by targeted biochemistry, was used to predict NulO types (i.e., neuraminic, legionaminic, or pseudaminic acids) expressed by various organisms. This approach uncovered previously unreported occurrences of Sia pathways in pathogenic and symbiotic bacteria and identified at least one instance in which a human archaeal symbiont tentatively reported to express Sias in fact expressed the related pseudaminic acid structure. Evaluation of targeted phylogenies and protein domain organization revealed that the “unique” Sia biosynthetic pathway of animals was instead a much more ancient innovation. Pathway phylogenies suggest that bacterial pathogens may have acquired Sia expression via adaptation of pathways for legionaminic acid biosynthesis, one of at least 3 evolutionary paths for de novo Sia synthesis. Together, these data indicate that some of the long-standing paradigms in Sia biology should be reconsidered in a wider evolutionary context of the extended family of NulO sugars.
Journal of Clinical Investigation | 2016
Peter Agre; Carolyn R. Bertozzi; Mina J. Bissell; Kevin P. Campbell; Richard D. Cummings; Umesh R. Desai; Mary K. Estes; Terence R. Flotte; Guy Fogleman; Fred H. Gage; David Ginsburg; Jeffrey Ivan Gordon; Gerald W. Hart; Vincent C. Hascall; Laura L. Kiessling; Stuart Kornfeld; John B. Lowe; John Magnani; Lara K. Mahal; Ruslan Medzhitov; Richard J. Roberts; Robert Sackstein; Rita Sarkar; Ronald L. Schnaar; Nancy B. Schwartz; Ajit Varki; David R. Walt; Irving L. Weissman
This position statement originated from a working group meeting convened on April 15, 2015, by the NHLBI and incorporates follow-up contributions by the participants as well as other thought leaders subsequently consulted, who together represent research fields relevant to all branches of the NIH. The group was deliberately composed not only of individuals with a current research emphasis in the glycosciences, but also of many experts from other fields, who evinced a strong interest in being involved in the discussions. The original goal was to discuss the value of creating centers of excellence for training the next generation of biomedical investigators in the glycosciences. A broader theme that emerged was the urgent need to bring the glycosciences back into the mainstream of biology by integrating relevant education into the curricula of medical, graduate, and postgraduate training programs, thus generating a critical sustainable workforce that can advance the much-needed translation of glycosciences into a more complete understanding of biology and the enhanced practice of medicine.
Bioinformatics | 1988
Rodney J. Folz; Jeffrey Ivan Gordon
A new algorithm is presented which can be used to examine the physical-chemical properties of amino acids at sites of co- or post-translational processing. This algorithm has been incorporated into a computer program known as PARA-SITE. Thirty different parameters can be studied for amino acids which occupy comparable positions in naturally occurring proteins. PARA-SITE should aid in the design and interpretation of protein engineering experiments which seek to dissect structure/activity relationships.
BMJ Open | 2017
Mustafa Mahfuz; Subhasish Das; Ramendra N. Mazumder; M Masudur Rahman; Rashidul Haque; Muzibur Rahman Bhuiyan; Hasina Akhter; Md. Shafiqul Alam Sarker; Dinesh Mondal; Syed Shafi Ahmed Muaz; A. S. M. Bazlul Karim; Stephen M. Borowitz; Christopher A. Moskaluk; Michael J Barratt; William A. Petri; Jeffrey Ivan Gordon; Tahmeed Ahmed
Introduction Environmental enteric dysfunction (EED) is a subacute inflammatory condition of the small intestinal mucosa with unclear aetiology that may account for more than 40% of all cases of stunting. Currently, there are no universally accepted protocols for the diagnosis, treatment and ultimately prevention of EED. The Bangladesh Environmental Enteric Dysfunction (BEED) study is designed to validate non-invasive biomarkers of EED with small intestinal biopsy, better understand disease pathogenesis and identify potential therapeutic targets for interventions designed to control EED and stunting. Methods and analysis The BEED study is a community-based intervention where participants are recruited from three cohorts: stunted children aged 12–18 months (length for age Z-score (LAZ) <−2), at risk of stunting children aged 12–18 months (LAZ <−1 to −2) and malnourished adults aged 18–45 years (body mass index <18.5 kg/m2). After screening, participants eligible for study provide faecal, urine and plasma specimens to quantify the levels of candidate EED biomarkers before and after receiving a nutritional intervention. Participants who fail to respond to nutritional therapy are considered as the candidates for upper gastrointestinal endoscopy with biopsy. Histopathological scoring for EED will be performed on biopsies obtained from several locations within the proximal small intestine. Candidate EED biomarkers will be correlated with nutritional status, the results of histochemical and immunohistochemical analyses of epithelial and lamina propria cell populations, plus assessments of microbial community structure. Ethics and dissemination Ethics approval was obtained in all participating institutes. Results of this study will be submitted for publication in peer-reviewed journals. Trial registration number ClinicalTrials.gov ID: NCT02812615. Registered on 21 June 2016.
Archive | 2012
Jeffrey Ivan Gordon; Jeremiah J. Faith; Nathan P. Mcnulty; Federico E. Rey; Andrew M. Goodman; George Kallstrom; Vanessa K. Ridaura
Archive | 2009
Buck Sparrow Samuel; Elizabeth E. Hansen; Jeffrey Ivan Gordon
Archive | 1989
Robert Otto Heuckeroth; Steven Paul Adams; Jeffrey Ivan Gordon; George W. Gokel
Archive | 2001
Jeffrey Ivan Gordon; Lora V. Hooper; Thaddeus F. Stappenbeck; Per Falk; Lennart Hansson
Archive | 1990
Jeffrey Ivan Gordon; Steven Paul Adams; Robert Otto Heuckeroth